RxDoctor Payments Data

Brian Page, MD

Cardiovascular Disease · Buffalo, NYNPI 1700028933

Payments from drug & device makers

$783in general payments, 2019–2025

Across 27 payments — averaging $29.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$272
  • Amgen$141
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$138
  • Abiomed$57
  • Novo Nordisk$35
  • Astellas Pharma US Inc$29
  • plus $111 from 5 others

What the payments were for

  • Food & beverage$66685%
  • Education$11715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$783 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$49,770
Medicare patients
738
Services billed
1,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban263$362,190
EntrestoSacubitril/Valsartan66$83,392
JardianceEmpagliflozin66$62,510
Repatha SureclickEvolocumab78$58,930
FarxigaDapagliflozin Propanediol23$32,350
XareltoRivaroxaban20$15,702
BrilintaTicagrelor16$14,132
Praluent PenAlirocumab27$13,563
OzempicSemaglutide11$9,047
LokelmaSodium Zirconium Cyclosilicate11$8,695
Metoprolol Succinate276$5,832
Rosuvastatin Calcium117$2,592
Atorvastatin Calcium146$2,535
Bisoprolol Fumarate39$2,406
Ezetimibe84$2,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$362,190263 claims
NovartisEntresto$13$83,39266 claims
AstraZenecaFarxiga, Brilinta, Lokelma$272$55,17650 claims
Novo NordiskOzempic$35$9,04711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →